VivoSeq
Oncology

Brain Neoplasm

60

Pipeline Programs

0

Active Trials

30

Companies Involved

Brain Neoplasm is a moderately active landscape with 60 programs across 30 companies. The most active players are Gilead, Merck & Co., Stason. 38 therapies are approved with 3 more in late-stage development.

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

0/100

Mech. Concentration

5/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

90%

Small molecule

55 of 61 classified programs — the dominant modality here.

10%ALL OTHERSMonoclonal antibody47%Protein / enzyme23%

Small molecule leads; the ring shows all 61 classified programs, each share of the total. Modality classified for 100% of 61 pipeline programs.

Trial Status

1

clinical trials

Completed1 · 100%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)